Bivatuzumab mertansine is a combination of bivatuzumab, a humanized monoclonal antibody, and mertansine, a cytotoxic agent. It is designed for the treatment of squamous cell carcinoma.
| Property | Value |
|---|---|
| dbpedia-owl:abstract |
|
| dbpedia-owl:atcPrefix |
|
| dbpedia-owl:thumbnail | |
| dbpprop:atcPrefix |
|
| dbpprop:mabType |
|
| dbpprop:source |
|
| dbpprop:target |
|
| dbpprop:type |
|
| dbpprop:verifiedrevid |
|
| dbpprop:wikiPageUsesTemplate | |
| dcterms:subject | |
| rdf:type | |
| rdfs:comment |
|
| rdfs:label |
|
| owl:sameAs | |
| foaf:depiction | |
| foaf:page | |
| is dbpedia-owl:wikiPageRedirects of | |
| is owl:sameAs of | |
| is foaf:primaryTopic of |



